2026/05/19
WuXi AppTec, a global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), is adding significant new drug substance and drug product manufacturing capacity over the next two years across the United States, Europe, and Asia, to meet growing demand from its global customer base.
Read more2026/05/19
“Every drug can be made, and every disease can be treated.” Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to numerous partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. Find out how WuXi AppTec’s integrated CRDMO platform enables innovation, accelerates R&D, and advances more new therapies to patients around the world.
Read more2026/04/09
Since its founding in 2000, WuXi AppTec’s mission has remained constant: to help global customers and partners discover, develop, and manufacture pharmaceuticals and healthcare products to benefit patients in need.
Read more2026/04/08
In drug discovery, innovative ideas emerge every day: scientists uncover novel mechanisms for disease treatment, previously “undruggable targets” begin to come within reach, and new modalities show potential in addressing complex diseases. However, there is often still a gulf between promising science and real-life therapies.
Read more2026/04/08
WuXi AppTec has helped advance drug development programs worldwide through more than two decades of collaboration with innovators. Across thousands of partnerships, the company has built its reputation not only on scale, but on its ability to deliver efficiency, solve complex scientific challenges, and connect different players across the global life sciences ecosystem. Together, these capabilities have established WuXi AppTec as a trusted partner in bringing new medicines from concept to reality.
Read more